Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany
JAMA Internal Medicine · 01.09.2024 · 184 (9) · 1002
DOI: 10.1001/jamainternmed.2024.2559 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.09.2024. Verfasst von Kerstin N Vokinger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Zitieren
APA
Vokinger, K. N., Nussli, E., & Dusetzina, S. B. (2024). Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany. JAMA Internal Medicine, 184(9), 1002. https://doi.org/10.1001/jamainternmed.2024.2559
Vancouver
Vokinger KN, Nussli E, Dusetzina SB. Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany. JAMA Internal Medicine. 2024;184(9):1002. doi:10.1001/jamainternmed.2024.2559
BibTeX
@article{Vokinger2024,
author = {Vokinger, Kerstin N and Nussli, Emanuel and Dusetzina, Stacie B},
title = {Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {9},
pages = {1002},
doi = {10.1001/jamainternmed.2024.2559}
}
EUVIMED